Susquehanna International Group
MRSN

Susquehanna International Group’s Mersana Therapeutics MRSN Stock Holding History

Susquehanna International Group’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,812
Closed -$64.8K – 13094
2024
Q4 		$64.8K Sell
1,812
-60
-3% -$3.1K ﹤0.01% 11574
2024
Q3 		$88.5K Buy
1,872
+1,256
+204% +$55.4K ﹤0.01% 11123
2024
Q2 		$31K Sell
616
-4,828
-89% -$349K ﹤0.01% 11553
2024
Q1 		$610K Buy
+5,444
New +$541K ﹤0.01% 8036
2023
Q3 		– Sell
-4,856
Closed -$399K – 12600
2023
Q2 		$399K Buy
4,856
+3,600
+287% +$527K ﹤0.01% 8837
2023
Q1 		$129K Buy
+1,256
New +$176K ﹤0.01% 11057
2021
Q3 		– Sell
-3,816
Closed -$1.3M – 13251
2021
Q2 		$1.3M Sell
3,816
-2,048
-35% -$775K ﹤0.01% 7036
2021
Q1 		$2.37M Buy
5,864
+5,356
+1,054% +$2.6M ﹤0.01% 5501
2020
Q4 		$338K Sell
508
-4,720
-90% -$2.62M ﹤0.01% 9037
2020
Q3 		$2.43M Buy
5,228
+4,232
+425% +$2.14M ﹤0.01% 4249
2020
Q2 		$583K Buy
996
+596
+149% +$204K ﹤0.01% 7042
2020
Q1 		$58K Buy
+400
New +$69.9K ﹤0.01% 9606

Other funds holding MRSN

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's MRSN Position: Q3 2025 in Review

Susquehanna International Group sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 17,975 shares — an estimated $133K sold.

Susquehanna International Group first reported a position in MRSN in Q2 2019 and held it in 24 quarters. The position peaked at $2.13M in Q1 2021. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Susquehanna International Group reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 17,975 Mersana Therapeutics shares in Q3 2025, an estimated $133K.
  • Susquehanna International Group first reported a position in Mersana Therapeutics in Q2 2019 and held it in 24 quarters.
  • Susquehanna International Group's Mersana Therapeutics position peaked at $2.13M in Q1 2021.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.